Phase I
It was a busy week for clinical trial news. Read on for more information.
While the ATLAS platform has the potential to lead to an effective vaccine in itself, its greatest impact in the field of immunotherapy may be that it offers a new way of understanding how a tumor evades the therapy’s boundaries by identifying bad Inhibigens that lead to suppressive, or inhibitory, responses.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson all have trials of their respective vaccines underway in various age-groups.
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.
With the Pfizer-BioNTech and Moderna COVID-19 vaccines currently authorized in the U.S. and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for its one-shot vaccine.
California-based Avidity Biosciences has a goal of disrupting the way RNA-based therapies are delivered to patients through its Antibody-Oligonucleotide Conjugates (AOCs) platform.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.
PRESS RELEASES